You just read:

CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S

News provided by

CytRx Corporation

Apr 29, 2019, 09:00 ET